Management of older adults with multiple myeloma

Blood Reviews

Volumn 27, Issue 3, 2013, Pages 133-142

  Palumbo, Antonio ^a   Mina, Roberto ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

Bortezomib; Elderly patients; Fit; Lenalidomide; Multiple myeloma; Thalidomide; Unfit

Indexed keywords

ACETYLSALICYLIC ACID; ACICLOVIR; ANTIANEMIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; BORTEZOMIB; CARFILZOMIB; CLODRONIC ACID; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; ELOTUZUMAB; GRANULOCYTE COLONY STIMULATING FACTOR; LENALIDOMIDE; LOW MOLECULAR WEIGHT HEPARIN; MELPHALAN; PAMIDRONIC ACID; PLACEBO; POMALIDOMIDE; PREDNISONE; THALIDOMIDE; ZOLEDRONIC ACID;

AGED; ANEMIA; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BONE DISEASE; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CONSTIPATION; DEEP VEIN THROMBOSIS; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG MEGADOSE; DRUG WITHDRAWAL; EVENT FREE SURVIVAL; GASTROINTESTINAL SYMPTOM; GERIATRIC PATIENT; HEART DISEASE; HEMATOLOGIC DISEASE; HERPES ZOSTER; HUMAN; INCIDENCE; INFECTION; JAW OSTEONECROSIS; KIDNEY FAILURE; LOW DRUG DOSE; MINIMAL RESIDUAL DISEASE; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NEUROTOXICITY; NEUTROPENIA; OVERALL SURVIVAL; PATIENT SELECTION; PERIPHERAL NEUROPATHY; PNEUMONIA; PREVALENCE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RECOMMENDED DRUG DOSE; THROMBOCYTOPENIA; VENOUS THROMBOEMBOLISM;

AGE FACTORS; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MULTIPLE MYELOMA; RECURRENCE;

EID: 84877111787     PISSN: 0268960X     EISSN: 15321681     Source Type: Journal    
DOI: 10.1016/j.blre.2013.04.001     Document Type: Article

References (89)

1. Palumbo A., Anderson K. Multiple myeloma. N Engl J Med 2011, 364(11):1046-1060.
2. Brenner H., Gondos A., Pulte D. Recent major improvement in long-term survival of younger patients with multiple myeloma. Blood 2008, 111(5):2521-2526.
3. Keats J.J., Chesi M., Egan J.B., Garbitt V.M., Palmer S.E., Braggio E., et al. Clonal competition with alternating dominance in multiple myeloma. Blood 2012, 120(5):1067-1076.
4. Egan J.B., Shi C.-X., Tembe W., Christoforides A., Kurdoglu A., Sinari S., et al. Whole-genome sequencing of multiple myeloma from diagnosis to plasma cell leukemia reveals genomic initiating events, evolution, and clonal tides. Blood 2012, 120(5):1060-1066.
5. Morgan G.J., Kaiser M.F. How to use new biology to guide therapy in multiple myeloma. Hematology Am Soc Hematol Educ Program 2012, 2012:342-349.
6. Usmani S.Z., Crowley J., Hoering A., Mitchell A., Waheed S., Nair B., et al. Improvement in long-term outcomes with successive total therapy trials for multiple myeloma: are patients now being cured?. Leukemia 2013, 27(1):226-232.
7. Kumar S.K., Lee J.H., Lahuerta J.J., Morgan G., Richardson P.G., Crowley J., et al. Risk of progression and survival in multiple myeloma relapsing after therapy with imids and bortezomib: a multicenter international myeloma working group study. Leukemia 2012, 26(1):149-157.
8. Van de Velde H.J.K., Liu X., Chen G., Deraedt W., Bayssas M. Complete response correlates with long-term survival and progression-free survival in high-dose therapy in multiple myeloma. Haematologica 2007, 92(10):1399-1406.
9. Gay F., Larocca A., Wijermans P., Cavallo F., Rossi D., Schaafsma R., et al. Complete response correlates with long-term progression-free and overall survival in elderly myeloma treated with novel agents: analysis of 1175 patients. Blood 2011, 117(11):3025-3031.
10. Palumbo A., Bringhen S., Rossi D., Cavalli M., Larocca A., Ria R., et al. Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial. J Clin Oncol 2010, 28(34):5101-5109.
11. Morgan G.J., Gregory W.M., Davies F.E., Bell S.E., Szubert A.J., Brown J.M., et al. The role of maintenance thalidomide therapy in multiple myeloma: MRC Myeloma IX results and meta-analysis. Blood 2012, 119(1):7-15.
12. Palumbo A., Bringhen S., Cavalli M., Ria R., Offidani M., Patriarca F., et al. Bortezomib, melphalan, prednisone and thalidomide followed by maintenance with bortezomib and thalidomide (VMPT-VT) for initial treatment of elderly multiple myeloma patients: updated follow-up and impact of prognostic factors. ASH Annual Meeting Abstracts 2010, 116(21):620.
13. Palumbo A., Bringhen S., Rossi D., Cavalli M., Ria R., Gentilini S., et al. Overall survival benefit for bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide (VMPT-VT) versus bortezomib-melphalan-prednisone (VMP) in newly diagnosed multiple myeloma patients. ASH Annual Meeting Abstracts 2012, 120(21):200.
14. Palumbo A., Hajek R., Delforge M., Kropff M., Petrucci M.T., Catalano J., et al. Continuous lenalidomide treatment for newly diagnosed multiple myeloma. N Engl J Med 2012, 366(19):1759-1769.
15. Fayers P.M., Palumbo A., Hulin C., Waage A., Wijermans P., Beksaç M., et al. Thalidomide for previously untreated elderly patients with multiple myeloma: meta-analysis of 1685 individual patient data from 6 randomized clinical trials. Blood 2011, 118(5):1239-1247.
16. San Miguel J.F., Schlag R., Khuageva N.K., Dimopoulos M.A., Shpilberg O., Kropff M., et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 2008, 359(9):906-917.
17. Mateos M.-V., Oriol A., Martínez-López J., Gutiérrez N., Teruel A.I., López de la Guía A., et al. Maintenance therapy with bortezomib plus thalidomide or bortezomib plus prednisone in elderly multiple myeloma patients included in the GEM2005MAS65 trial. Blood 2012, 120(13):2581-2588.
18. Palumbo A., Bringhen S., Ludwig H., Dimopoulos M.A., Bladé J., Mateos M.V., et al. Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN). Blood 2011, 118(17):4519-4529.
19. Niesvizky R., Reeves J., Flinn I. Phase 3b upfront study: interim results from a community-based prospective randomized trial evaluating three bortezomib-based regimens in elderly, newly diagnosed multiple myeloma patients. EHA Annual Meeting 2010, 95(2):0358.
20. Howlade N., Noone A., Krapcho M., Neyman N., Aminou R., Altekruse S.F., et al. Seer Cancer Statistics Review, 1975-2009 (Vintage 2009 Populations) 2012, National Cancer Institute, Bethesda, MD, [http://seer.cancer.gov/csr/1975_2009_pops09/, based on November 2011 seer data submission, posted to the seer web site].
21. Kristinsson S.Y., Landgren O., Dickman P.W., Derolf A.R., Björkholm M. Patterns of survival in multiple myeloma: a population-based study of patients diagnosed in Sweden from 1973 to 2003. J Clin Oncol 2007, 25(15):1993-1999.
22. Hutchins L.F., Unger J.M., Crowley J.J., Coltman C.A., Albain K.S. Underrepresentation of patients 65years of age or older in cancer-treatment trials. N Engl J Med 1999, 341(27):2061-2067.
23. Fried L.P., Tangen C.M., Walston J., Newman A.B., Hirsch C., Gottdiener J., et al. Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci 2001, 56(3):M146-156.
24. Charlson M., Szatrowski T.P., Peterson J., Gold J. Validation of a combined comorbidity index. J Clin Epidemiol 1994, 47(11):1245-1251.
25. Palumbo A., Bringhen S., Petrucci M.T., Musto P., Rossini F., Nunzi M., et al. Intermediate-dose melphalan improves survival of myeloma patients aged 50 to 70: results of a randomized controlled trial. Blood 2004, 104(10):3052-3057.
26. Facon T., Mary J.Y., Hulin C., Benboubker L., Attal M., Pegourie B., et al. Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial. Lancet 2007, 370(9594):1209-1218.
27. Straka C., Schafer-Eckart K., Bassermann F., Hertenstein B., Engelhardt M., Salwender H., et al. Prospective randomized trial of Len/Dex induction followed by tandem mel140 with autologous blood stem cell transplantation and Len maintenance versus continued therapy with Len/Dex in myeloma patients age 60-75years: protocol-defined safety analysis after 100 patients. ASH Annual Meeting Abstracts 2012, 120(21):2012.
28. Harousseau J.L., Mathiot C., Attal M., Marit G., Caillot D., Mohty M.M.M., et al. Velcade/dexamethasone (Vel/D) versus VAD as induction treatment prior to autologous stem cell transplantation (ASCT) in newly diagnosed multiple myeloma (MM): updated results of the IFM 2005/01 trial. ASH Annual Meeting Abstracts 2007, 110(11):450.
29. Weber D.M., Chen C., Niesvizky R., Wang M., Belch A., Stadtmauer E.A., et al. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med 2007, 357(21):2133-2142.
30. Palumbo A., Gay F., Falco P., Crippa C., Montefusco V., Patriarca F., et al. Bortezomib as induction before autologous transplantation, followed by lenalidomide as consolidation-maintenance in untreated multiple myeloma patients. J Clin Oncol 2010, 28(5):800-807.
31. Palumbo A., Cavallo F., Hardan I., Lupo B., Redoglia V., Levin M., et al. Melphalan/prednisone/lenalidomide (MPR) versus high-dose melphalan and autologous transplantation (MEL200) in newly diagnosed multiple myeloma (MM) patients <65years: results of a randomized phase iii study. ASH Annual Meeting Abstracts 2011, 118(21):3069.
32. Ludwig H., Hajek R., Tóthová E., Drach J., Adam Z., Labar B., et al. Thalidomide-dexamethasone compared with melphalan-prednisolone in elderly patients with multiple myeloma. Blood 2009, 113(15):3435-3442.
33. Hulin C., Facon T., Rodon P., Pegourie B., Benboubker L., Doyen C., et al. Efficacy of melphalan and prednisone plus thalidomide in patients older than 75years with newly diagnosed multiple myeloma: IFM 01/01 trial. J Clin Oncol 2009, 27(22):3664-3670.
34. Palumbo A., Bringhen S., Caravita T., Merla E., Capparella V., Callea V., et al. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. Lancet 2006, 367(9513):825-831.
35. Wijermans P., Schaafsma M., Termorshuizen F., et al. Phase III study of the value of thalidomide added to melphalan plus prednisone in elderly patients with newly diagnosed multiple myeloma: the HOVON 49 study. J Clin Oncol 2010, 28(19):3160-3166.
36. Waage A., Gimsing P., Fayers P., et al. Melphalan and prednisone plus thalidomide or placebo in elderly patients with multiple myeloma. Blood 2010, 116(9):1405-1412.
37. Beksac M., Haznedar R., Firatli-Tuglular T., Ozdogu H., Aydogdu I., Konuk N., et al. Addition of thalidomide to oral melphalan/prednisone in patients with multiple myeloma not eligible for transplantation: results of a randomized trial from the Turkish Myeloma Study Group. Eur J Haematol 2011, 86(1):16-22.
38. Palumbo A., Waage A., Hulin C., Beksac M., Zweegman S., Gay F., et al. Safety of thalidomide in newly diagnosed elderly myeloma patients: a meta-analysis of data from individual patients in six randomized trials. Haematologica 2013, 98(1):87-94.
39. Morgan G.J., Davies F.E., Gregory W.M., Russell N.H., Bell S.E., Szubert A.J., et al. Cyclophosphamide, thalidomide, and dexamethasone (CTD) as initial therapy for patients with multiple myeloma unsuitable for autologous transplantation. Blood 2011, 118(5):1231-1238.
40. Dimopoulos M., Spencer A., Attal M., Prince H.M., Harousseau J.L., Dmoszynska A., et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med 2007, 357(21):2123-2132.
41. Zonder J.A., Crowley J., Hussein M.A., Bolejack V., Moore D.F., Whittenberger B.F., et al. Superiority of lenalidomide (Len) plus high-dose dexamethasone (HD) compared to HD alone as treatment of newly-diagnosed multiple myeloma (NDMM): results of the randomized, double-blinded, placebo-controlled SWOG trial S0232. ASH Annual Meeting Abstracts 2007, 110(11):77.
42. Rajkumar S.V., Jacobus S., Callander N.S., Fonseca R., Vesole D.H., Williams M.E., et al. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet Oncol 2010, 11(1):29-37.
43. San Miguel J.F., Schlag R., Khuageva N.K., Dimopoulos M.A., Shpilberg O., Kropff M., et al. Continued overall survival benefit after 5years' follow-up with bortezomib-melphalan-prednisone (VMP) versus melphalan-prednisone (MP) in patients with previously untreated multiple myeloma, and no increased risk of second primary malignancies: final results of the phase 3 vista trial. ASH Annual Meeting Abstracts 2011, 118(21):476.
44. Mateos M.-V., Oriol A., Martínez-López J., Gutiérrez N., Teruel A.I., de Paz R., et al. Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial. Lancet Oncol 2010, 11(10):934-941.
45. Niesvizky R., Flinn I.W., Rifkin R., Gabrail N., Charu V., Clowney B., et al. Efficacy and safety of three bortezomib-based combinations in elderly, newly diagnosed multiple myeloma patients: results from all randomized patients in the community-based, phase 3b UPFRONT study. ASH Annual Meeting Abstracts 2011, 118(21):478.
46. Reeder C.B., Reece D.E., Kukreti V., Chen C., Trudel S., Hentz J., et al. Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial. Leukemia 2009, 23(7):1337-1341.
47. Reeder C.B., Reece D.E., Kukreti V., Chen C., Trudel S., Laumann K., et al. Once- versus twice-weekly bortezomib induction therapy with cybord in newly diagnosed multiple myeloma. Blood 2010, 115(16):3416-3417.
48. Richardson P.G., Weller E., Lonial S., Jakubowiak A.J., Jagannath S., Raje N.S., et al. Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood 2010, 116(5):679-686.
49. Kumar S., Flinn I., Richardson P.G., Hari P., Callander N., Noga S.J., et al. Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma. Blood 2012, 119(19):4375-4382.
50. Bringhen S., Larocca A., Rossi D., Cavalli M., Genuardi M., Ria R., et al. Efficacy and safety of once-weekly bortezomib in multiple myeloma patients. Blood 2010, 116(23):4745-4753.
51. Moreau P., Pylypenko H., Grosicki S., Karamanesht I., Leleu X., Grishunina M., et al. Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. Lancet Oncol 2011, 12(5):431-440.
52. Falco P., Cavallo F., Larocca A., Rossi D., Guglielmelli T., Rocci A., et al. Lenalidomide-prednisone induction followed by lenalidomide-melphalan-prednisone consolidation and lenalidomide-prednisone maintenance in newly diagnosed elderly unfit myeloma patients. Leukemia 2013, 27(3):695-701.
53. Anderson K.C., Kyle R.A., Rajkumar S.V., Stewart A.K., Weber D., Richardson P. Clinically relevant end points and new drug approvals for myeloma. Leukemia 2008, 22(2):231-239.
54. Kastritis E., Palumbo A., Dimopoulos M.A. Treatment of relapsed/refractory multiple myeloma. Semin Hematol 2009, 46(2):143-157.
55. Jagannath S., Richardson P.G., Barlogie B., Berenson J.R., Singhal S., Irwin D., et al. Bortezomib in combination with dexamethasone for the treatment of patients with relapsed and/or refractory multiple myeloma with less than optimal response to bortezomib alone. Haematologica 2006, 91(7):929-934.
56. Jagannath S., Barlogie B., Berenson J.R., Siegel D.S., Irwin D., Richardson P.G., et al. Updated survival analyses after prolonged follow-up of the phase 2, multicenter CREST study of bortezomib in relapsed or refractory multiple myeloma. Br J Haematol 2008, 143(4):537-540.
57. Touzeau C., Blin N., Clavert A., Roland V., Loirat M., Tessoulin B., et al. Efficacy of lenalidomide plus dexamethasone in patients older than 75years with relapsed multiple myeloma. Leuk Lymphoma 2012, 53(7):1318-1320.
58. Richardson P.G., Sonneveld P., Schuster M.W., Irwin D., Stadtmauer E.A., Facon T., et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005, 352(24):2487-2498.
59. Richardson P.G., Sonneveld P., Schuster M., Irwin D., Stadtmauer E.A., Facon T., et al. Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the apex trial. Blood 2007, 110(10):3557-3560.
60. Palumbo A., Sezer O., Kyle R., Miguel J.S., Orlowski R.Z., Moreau P., et al. International Myeloma Working Group guidelines for the management of multiple myeloma patients ineligible for standard high-dose chemotherapy with autologous stem cell transplantation. Leukemia 2009, 23(10):1716-1730.
61. Wang M., Dimopoulos M.A., Chen C., Cibeira M.T., Attal M., Spencer A., et al. Lenalidomide plus dexamethasone is more effective than dexamethasone alone in patients with relapsed or refractory multiple myeloma regardless of prior thalidomide exposure. Blood 2008, 112(12):4445-4451.
62. Singhal S., Siegel D.S., Martin T., Vij R., Wang L., Jakubowiak A.J., et al. Integrated safety from phase 2 studies of monotherapy carfilzomib in patients with relapsed and refractory multiple myeloma (MM): an updated analysis. ASH Annual Meeting Abstracts 2011, 118(21):1876.
63. Jagannath S., Vij R., Stewart K., Somlo G., Jakubowiak A., Trudel S., et al. Final results of PX-171-003-A0, part 1 of an open-label, single-arm, phase II study of carfilzomib (CFZ) in patients (pts) with relapsed and refractory multiple myeloma (MM). J Clin Oncol 2009, 27(Suppl. 15s). [abstr 8504].
64. diCapua Siegel D.S., Martin T., Wang M., Vij R., Jakubowiak A.J., Jagannath S., et al. Results of PX-171-003-A1, an open-label, single-arm, phase 2 (Ph 2) study of carfilzomib (CFZ) in patients (pts) with relapsed and refractory multiple myeloma (MM). ASH Annual Meeting Abstracts 2010, 116(21):985.
65. Vij R., Wang M., Kaufman J.L., Lonial S., Jakubowiak A.J., Stewart A.K., et al. An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naïve patients with relapsed and/or refractory multiple myeloma. Blood 2012, 119(24):5661-5670.
66. Bensinger W., Wang M., Orlowski R.Z., Alsina M., Martin T., Singhal S., et al. Dose-escalation study of carfilzomib (CFZ) plus lenalidomide (LEN) plus low-dose dexamethasone (DEX) (CRd) in relapsed/refractory multiple myeloma (R/R MM). J Clin Oncol 2010, 28(15):8029.
67. Palumbo A., Larocca A., Montefusco V., Rossi D., Carella A.M., Mina R., et al. Pomalidomide cyclophosphamide and prednisone (PCP) treatment for relapsed/refractory multiple myeloma. ASH Annual Meeting Abstracts 2012, 120(21):446.
68. Mark T.M., Boyer A., Rossi A.C., Shah M., Pearse R.N., Zafar F., et al. CLAPD (clarithromycin, pomalidomide, dexamethasone) therapy in relapsed or refractory multiple myeloma. ASH Annual Meeting Abstracts 2012, 120(21):77.
69. Birgegård G., Gascón P., Ludwig H. Evaluation of anaemia in patients with multiple myeloma and lymphoma: findings of the European Cancer Anaemia Survey. Eur J Haematol 2006, 77(5):378-386.
70. ™ cancer- and chemotherapy-induced anemia (version 2.2011) http://www.nccn.org/professionals/physician_gls/pdf/anemia.pdf.
71. Palumbo A., Bladé J., Boccadoro M., Palladino C., Davies F., Dimopoulos M., et al. How to manage neutropenia in multiple myeloma. Clin Lymphoma Myeloma Leuk 2012, 12(1):5-11.
72. Gay F., Palumbo A. Management of older patients with multiple myeloma. Blood Rev 2011, 25(2):65-73.
73. Richardson P.G., Briemberg H., Jagannath S., Wen P.Y., Barlogie B., Berenson J., et al. Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J Clin Oncol 2006, 24(19):3113-3120.
74. Delforge M., Bladé J., Dimopoulos M.A., Facon T., Kropff M., Ludwig H., et al. Treatment-related peripheral neuropathy in multiple myeloma: the challenge continues. Lancet Oncol 2010, 11(11):1086-1095.
75. Palumbo A., Facon T., Sonneveld P., Bladè J., Offidani M., Gay F., et al. Thalidomide for treatment of multiple myeloma: 10years later. Blood 2008, 111(8):3968-3977.
76. Barlogie B., Desikan R., Eddlemon P., Spencer T., Zeldis J., Munshi N., et al. Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients. Blood 2001, 98(2):492-494.
77. Richardson P.G., Schlossman R.L., Weller E., Hideshima T., Mitsiades C., Davies F., et al. Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood 2002, 100(9):3063-3067.
78. Palumbo A., Rajkumar S.V., Dimopoulos M.A., Richardson P.G., San Miguel J., Barlogie B., et al. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia 2008, 22(2):414-423.
79. Alexanian R., Dimopoulos M.A., Delasalle K., Barlogie B. Primary dexamethasone treatment of multiple myeloma. Blood 1992, 80(4):887-890.
80. Dimopoulos M.A., Richardson P.G., Schlag R., Khuageva N.K., Shpilberg O., Kastritis E., et al. VMP (bortezomib, melphalan, and prednisone) is active and well tolerated in newly diagnosed patients with multiple myeloma with moderately impaired renal function, and results in reversal of renal impairment: cohort analysis of the phase III VISTA study. J Clin Oncol 2009, 27(36):6086-6093.
81. Dimopoulos M.A., Terpos E., Chanan-Khan A., Khuageva N.K., Shpilberg O., Kastritis E., et al. Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group. J Clin Oncol 2010, 28(33):4976-4984.
82. Celgene corporation Revlimid package insert. Summit, NJ available at:, [accessed July 2012]. http://www.revlimid.com/pdf/revlimid_pi.pdf.
83. Palumbo A., Gay F. How to treat elderly patients with multiple myeloma: combination of therapy or sequencing. Hematology Am Soc Hematol Educ Program 2009, 566-577.
84. Chanan-Khan A., Sonneveld P., Schuster M.W., Stadtmauer E.A., Facon T., Harousseau J.L., et al. Analysis of herpes zoster events among bortezomib-treated patients in the phase III APEX study. J Clin Oncol 2008, 26(29):4784-4790.
85. Morgan G.J., Davies F.E., Gregory W.M., Cocks K., Bell S.E., Szubert A.J., et al. First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial. Lancet 2010, 376(9757):1989-1999.
86. Morgan G.J., Child J.A., Gregory W.M., Szubert A.J., Cocks K., Bell S.E., et al. Effects of zoledronic acid versus clodronic acid on skeletal morbidity in patients with newly diagnosed multiple myeloma (MRC myeloma IX): secondary outcomes from a randomised controlled trial. Lancet Oncol 2011, 12(8):743-752.
87. Rosen L.S., Gordon D., Kaminski M., Howell A., Belch A., Mackey J., et al. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. Cancer 2003, 98(8):1735-1744.
88. Kyle R.A., Yee G.C., Somerfield M.R., Flynn P.J., Halabi S., Jagannath S., et al. American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma. J Clin Oncol 2007, 25(17):2464-2472.
89. Terpos E., Sezer O., Croucher P.I., García-Sanz R., Boccadoro M., San Miguel J., et al. The use of bisphosphonates in multiple myeloma: recommendations of an expert panel on behalf of the European Myeloma Network. Ann Oncol 2009, 20(8):1303-1317.